中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 4
Apr.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(4): 880-882

Local embolization combined with targeted comprehensive immunotherapy in treatment of sarcomatoid hepatocellular carcinoma: A case report

DOI: 10.3969/j.issn.1001-5256.2022.04.026
  • 1.

    School of Clinical Medicine, Guizhou Medical University, Guiyang 550004, China

  • 2.

    Department of Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China

  • 3.

    Peking University 302 Clinical Medical School, Beijing 100039, China

  • 4.

    Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China

Research funding:

Special Fund for Outstanding Young Scientific and Technological Talents of Guizhou Province (Talents of Guizhou Kehe platform[2019]5647)

More Information
  • Corresponding author: ZUO Shi, drzuoshi@qq.com(ORCID: 0000-0001-9092-8723)
  • Received Date: 2021-07-24
  • Published Date: 2022-04-20
    Abstract
    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    WU L, TSILIMIGRAS DI, FAROOQ A, et al. Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: A population-based analysis[J]. Cancer, 2019, 125(21): 3767-3775. DOI: 10.1002/cncr.32396.
    [2]
    GIANNIS D, MORSY S, GEROPOULOS G, et al. The epidemiology, staging and outcomes of sarcomatoid hepatocellular carcinoma: A SEER population analysis[J]. In Vivo, 2021, 35(1): 393-399. DOI: 10.21873/invivo.12270.
    [3]
    KIM SJ, RHU J, KIM JM, et al. Surgical treatment outcomes of primary hepatic sarcomas: A single-center experience[J]. World J Hepatol, 2021, 13(5): 584-594. DOI: 10.4254/wjh.v13.i5.584.
    [4]
    ZHANG H, CHAI S, CHEN L, et al. MRI features of hepatic sarcomatoid carcinoma different from hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Front Oncol, 2021, 11: 611738. DOI: 10.3389/fonc.2021.611738.
    [5]
    WANG QB, CUI BK, WENG JM, et al. Clinicopathological characteristics and outcome of primary sarcomatoid carcinoma and carcinosarcoma of the liver[J]. J Gastrointest Surg, 2012, 16(9): 1715-1726. DOI: 10.1007/s11605-012-1946-y.
    [6]
    LI Z, WU X, BI X, et al. Clinicopathological features and surgical outcomes of four rare subtypes of primary liver carcinoma[J]. Chin J Cancer Res, 2018, 30(3): 364-372. DOI: 10.21147/j.issn.1000-9604.2018.03.08.
    [7]
    FORBES A, PORTMANN B, JOHNSON P, et al. Hepatic sarcomas in adults: A review of 25 cases[J]. Gut, 1987, 28(6): 668-674. DOI: 10.1136/gut.28.6.668.
    [8]
    KIM DK, KIM BR, JEONG JS, et al. Analysis of intrahepatic sarcomatoid cholangiocarcinoma: Experience from 11 cases within 17 years[J]. World J Gastroenterol, 2019, 25(5): 608-621. DOI: 10.3748/wjg.v25.i5.608.
    [9]
    MORISUE R, KOJIMA M, SUZUKI T, et al. Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses[J]. Int J Cancer, 2021, 149(3): 546-560. DOI: 10.1002/ijc.33545.
    [10]
    ERIGUCHI N, AOYAGI S, OKUDA K, et al. Unusual liver carcinomas with sarcomatous features: Analysis of four cases[J]. Surg Today, 2001, 31(6): 530-533. DOI: 10.1007/s005950170116.
    [11]
    CHENG JY, WANG CH, CHEN JH, et al. Sarcoma- toid carcinomas of the liver, gallbladder, and pancreas: A clinicopathological portrait and literature review[J]. J Clin Hepatol, 2020, 36(10): 2270-2273. DOI: 10.3969/j.issn.1001-5256.2020.10.022.

    程捷瑶, 王沧海, 陈建宏, 等. 肝胆胰肉瘤样癌的临床病理特征及文献复习[J]. 临床肝胆病杂志, 2020, 36(10): 2270-2273. DOI: 10.3969/j.issn.1001-5256.2020.10.022.
    [12]
    LUO C, XIN H, YIN D, et al. Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma[J]. Aging (Albany NY), 2021, 13(11): 15126-15138. DOI: 10.18632/aging.203076.
    [13]
    QIAN XH, GAO BQ, WANG WL. Primary hepatic sarcomatous carcinoma misdiagnosed as liver abscess: A case report[J]. J Clin Hepatol, 2020, 36(1): 158-160. DOI: 10.3969.j.issn.1001-5256.2020.01.035

    钱晓晖, 高炳强, 王伟林. 原发性肝肉瘤样癌误诊为肝脓肿1例报告[J]. 临床肝胆病杂志, 2020, 36(1): 158-160. DOI: 10.3969.j.issn.1001-5256.2020.01.035.
    [14]
    YANG Z, LV K, ZHAO Y, et al. Sarcomatoid hepatocellular carcinoma mimicking hepatic abscess: A case report[J]. Medicine (Baltimore), 2020, 99(39): e22489. DOI: 10.1097/MD.0000000000022489.
    [15]
    SHAH V, ARORA A, TYAGI P, et al. Intrahepatic cholangiocarcinoma masquerading as liver abscess[J]. J Clin Exp Hepatol, 2015, 5(1): 89-92. DOI: 10.1016/j.jceh.2014.12.006.
    [16]
    CHEN LD, RUAN SM, LIANG JY, et al. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound[J]. World J Gastroenterol, 2018, 24(33): 3786-3798. DOI: 10.3748/wjg.v24.i33.3786.
    [17]
    WEITZ J, KLIMSTRA DS, CYMES K, et al. Management of primary liver sarcomas[J]. Cancer, 2007, 109(7): 1391-1396. DOI: 10.1002/cncr.22530.
    [18]
    WU Z, WEI Y, CAI Z, et al. Long-term survival outcomes of undifferentiated embryonal sarcoma of the liver: A pooled analysis of 308 patients[J]. ANZ J Surg, 2020, 90(9): 1615-1620. DOI: 10.1111/ans.15684.
    [19]
    HOOS A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations[J]. Nat Rev Drug Discov, 2016, 15(4): 235-247. DOI: 10.1038/nrd.2015.35.
    [20]
    ZHU SG, LI HB, YUAN ZN, et al. Achievement of complete response to nivolumab in a patient with advanced sarcomatoid hepatocellular carcinoma: A case report[J]. World J Gastrointest Oncol, 2020, 12(10): 1209-1215. DOI: 10.4251/wjgo.v12.i10.1209.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (637) PDF downloads(48) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return